| Abstract | BACKGROUND: Although systemic corticosteroids are effective against cutaneous sarcoidosis, alternative therapies are needed. OBJECTIVE: We sought to assess the efficacy and tolerance of thalidomide for cutaneous sarcoidosis. METHODS: We performed a retrospective evaluation of thalidomide (100-200 mg/d) in 12 consecutive patients with cutaneous sarcoidosis treated in a university hospital between 2000 and 2002. RESULTS: Cutaneous lesions regressed within 1 to 5 months, with an average time of 2 to 3 months for 10 patients. In all, 4 patients achieved complete responses, 6 had partial responses, and 2 had no regression. Nasopharyngeal, pulmonary neurologic, and hepatic symptoms were also attenuated. Thalidomide was well tolerated. The main adverse effect was deep vein thrombosis in 1 patient. CONCLUSION: Thalidomide efficacy and tolerance in patients with cutaneous sarcoidosis merits further evaluation in a controlled trial. |
| Authors | Yên Thi Nguyen, Alain Dupuy, Florence Cordoliani, Marie Dominique Vignon-Pennamen, Céleste Lebbé, Patrice Morel, Michel Rybojad
(Affiliation: Dermatology Department, Hôspital Saint-Louis, Paris, France.)
|
| Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 50
Issue 2
Pg. 235-41
(Feb 2004)
ISSN: 0190-9622 United States |
| PMID | 14726878
(Publication Type: Clinical Trial, Journal Article)
|
| Chemical References |
- Immunosuppressive Agents
- Thalidomide
|
| Topics |
- Adult
- Dose-Response Relationship, Drug
- Female
- Humans
- Immunosuppressive Agents
(administration & dosage, adverse effects, therapeutic use)
- Male
- Middle Aged
- Retrospective Studies
- Sarcoidosis
(drug therapy, pathology)
- Skin Diseases
(drug therapy, pathology)
- Thalidomide
(administration & dosage, adverse effects, therapeutic use)
- Treatment Outcome
- Venous Thrombosis
(chemically induced)
|
